Komipharm International Co., Ltd.'s Equity Buyback announced on March 21, 2024, has closed with 241,545 shares, representing 0.35% for KRW 987.93 million.
Komipharm International Co Ltd is a Korea-based company principally engaged in the development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The Companyâs main products include veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle, vaccines for infectious bronchitis and Newcastle disease, and canine respiratory infection killed vaccines, and veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis, swine erysipelas, septicemia, leptospirosis and bacterial diseases for livestock. The Company also engages in research and development of anticancer drugs and cancer pain-relieving agents. In addition, the Company provides services such as pathological biopsies, serum tests, and bacteria tests.
Komipharm International Co., Ltd.'s Equity Buyback announced on March 21, 2024, has closed with 241,545 shares, representing 0.35% for KRW 987.93 million.